Targeting RET-rearranged non-small-cell lung cancer: future prospects

References

• NovelloSBarlesiFCalifanoRMetastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201627suppl 5v1v2727664245
   PubMed Web of Science ®Google Scholar
• BronteGRizzoSLa PagliaLDriver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinomaCancer Treat Rev201036Suppl 3S21S2921129606
   PubMed Web of Science ®Google Scholar
• RolfoCMackPCScagliottiGVLiquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLCJ Thorac Oncol20181391248126829885479
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular profiling of lung adenocarcinomaNature2014511751154355025079552
   PubMed Web of Science ®Google Scholar
• TakahashiMRitzJCooperGMActivation of a novel human transforming gene, RET, by DNA rearrangementCell19854225815882992805
   PubMed Web of Science ®Google Scholar
• TakahashiMRet protooncogene and human-diseases – reviewInt J Oncol199441818421566893
   PubMed Web of Science ®Google Scholar
• de GraaffESrinivasSKilkennyCDifferential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesisGenes Dev200115182433244411562352
   PubMed Web of Science ®Google Scholar
• ChiXMichosOShakyaRRet-dependent cell rearrangements in the Wolffian duct epithelium initiate ureteric bud morphogenesisDev Cell200917219920919686681
   PubMed Web of Science ®Google Scholar
• AiraksinenMSSaarmaMThe GDNF family: signalling, biological functions and therapeutic valueNat Rev Neurosci20023538339411988777
   PubMed Web of Science ®Google Scholar
• ArighiEBorrelloMGSariolaHRET tyrosine kinase signaling in development and cancerCytokine Growth Factor Rev2005164–544146715982921
   PubMed Web of Science ®Google Scholar
• MarxSJAgarwalSKKesterMBMultiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasiasRecent Prog Horm Res19995439743810548885
   PubMedGoogle Scholar
• HendyGNKajiHCanaffLCellular functions of meninAdv Exp Med Biol2009668375020175451
   PubMed Web of Science ®Google Scholar
• MarxSJMolecular genetics of multiple endocrine neoplasia types 1 and 2Nat Rev Cancer20055536737515864278
   PubMed Web of Science ®Google Scholar
• EngCClaytonDSchuffeneckerIThe relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium AnalysisJAMA19962761915758918855
   PubMed Web of Science ®Google Scholar
• CerratoAde FalcoVSantoroMMolecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targetsJ Mol Endocrinol200943414315519383830
   PubMed Web of Science ®Google Scholar
• PrescottJDZeigerMAThe RET oncogene in papillary thyroid carcinomaCancer2015121132137214625731779
   PubMed Web of Science ®Google Scholar
• SantoroMMelilloRMFuscoARET/PTC activation in papillary thyroid carcinoma: European Journal of endocrinology Prize LectureEur J Endocrinol2006155564565317062879
   PubMed Web of Science ®Google Scholar
• JuYSLeeWCShinJYA transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Res201222343644522194472
   PubMed Web of Science ®Google Scholar
• DacicSLuvisonAEvdokimovaVRET rearrangements in lung adenocarcinoma and radiationJ Thorac Oncol20149111812024346100
   PubMed Web of Science ®Google Scholar
• WangRHuHPanYRET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancerJ Clin Oncol201230354352435923150706
   PubMed Web of Science ®Google Scholar
• KatoSSubbiahVMarchlikEElkinSKCarterJLKurzrockRRET aberrations in diverse cancers: next-generation sequencing of 4,871 patientsClin Cancer Res20172381988199727683183
   PubMed Web of Science ®Google Scholar
• ChaoBHBriesewitzRVillalona-CaleroMARET fusion genes in non-small-cell lung cancerJ Clin Oncol201230354439444123150705
   PubMed Web of Science ®Google Scholar
• FerraraRAugerNAuclinEBesseBClinical and translational implications of RET rearrangements in non-small cell lung cancerJ Thorac Oncol2018131274529128428
   PubMed Web of Science ®Google Scholar
• PlenkerDRiedelMBrägelmannJDrugging the catalytically inactive state of RET kinase in RET-rearranged tumorsSci Transl Med20179394eaah614428615362
   PubMed Web of Science ®Google Scholar
• Plaza-MenachoIMologniLMcDonaldNQMechanisms of RET signaling in cancer: current and future implications for targeted therapyCell Signal20142681743175224705026
   PubMed Web of Science ®Google Scholar
• MatsubaraDKanaiYIshikawaSIdentification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/adJ Thorac Oncol20127121872187623154560
   PubMed Web of Science ®Google Scholar
• SaitoMIshigameTTsutaKKumamotoKImaiTKohnoTA mouse model of KIF5B-RET fusion-dependent lung tumorigenesisCarcinogenesis201435112452245625064355
   PubMed Web of Science ®Google Scholar
• LiGGSomwarRJosephJAntitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutationsClin Cancer Res201723122981299028011461
   PubMed Web of Science ®Google Scholar
• SubbiahVGainorJFRahalRPrecision targeted therapy with BLU-667 for RET-driven cancersCancer Discov20188783684929657135
   PubMed Web of Science ®Google Scholar
• SubbiahVVelchetiVTuchBBSelective RET kinase inhibition for patients with RET-altered cancersAnn Oncol20182981869187629912274
   PubMed Web of Science ®Google Scholar
• GautschiOMiliaJFilleronTTargeting RET in patients with RET -rearranged lung cancers: results from the Global, Multicenter RET RegistryJ Clin Oncol201735131403141028447912
   PubMed Web of Science ®Google Scholar
• DrilonARekhtmanNArcilaMCabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trialLancet Oncol201617121653166027825636
   PubMed Web of Science ®Google Scholar
• LeeSHLeeJKAhnMJVandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trialAnn Oncol201728229229727803005
   PubMed Web of Science ®Google Scholar
• YohKSetoTSatouchiMVandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trialLancet Respir Med201751425027825616
   PubMed Web of Science ®Google Scholar
• HoriikeATakeuchiKUenamiTSorafenib treatment for patients with Ret fusion-positive non-small cell lung cancerLung Cancer201693434626898613
   PubMed Web of Science ®Google Scholar
• LipsonDCapellettiMYelenskyRIdentification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNat Med201218338238422327622
   PubMed Web of Science ®Google Scholar
• VelchetiVHidaTReckampKLPhase 2 study of lenvatinib (Ln) in patients (PTS) with Ret fusion-positive adenocarcinoma of the lungAnn Oncol201627suppl_61204PD
   Google Scholar
• KohnoTIchikawaHTotokiYKIF5B-RET fusions in lung adenocarcinomaNat Med201218337537722327624
   PubMed Web of Science ®Google Scholar
• RichardsonDSGujralTSPengSAsaSLMulliganLMTranscript level modulates the inherent oncogenicity of RET/PTC oncoproteinsCancer Res200969114861486919487296
   PubMed Web of Science ®Google Scholar
• DasTKCaganRLKIF5B-RET oncoprotein signals through a multi-kinase signaling hubCell Reports201720102368238328877471
   PubMed Web of Science ®Google Scholar
• LiuXShenTMooersBHMHilbergFWuJDrug resistance profiles of mutations in the RET kinase domainBr J Pharmacol2018175173504351529908090
   PubMed Web of Science ®Google Scholar
• NakaokuTKohnoTArakiMA secondary RET mutation in the activation loop conferring resistance to vandetanibNat Commun20189162529434222
   PubMed Web of Science ®Google Scholar
• Dagogo-JackIStevensSELinJJEmergence of a RET V804M gatekeeper mutation during treatment with vandetanib in RET-Rearranged NSCLCJ Thorac Oncol20181311e226e22730368414
   PubMed Web of Science ®Google Scholar
• GainorJFDardaeiLYodaSMolecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancerCancer Discov20166101118113327432227
   PubMed Web of Science ®Google Scholar
• ChangHSungJHMoonSUKimHSKimJWLeeJSEGF induced RET inhibitor resistance in CCDC6-RET lung cancer cellsYonsei Med J201758191827873490
   PubMed Web of Science ®Google Scholar
• VaishnaviASchubertLRixUEGFR mediates responses to small-molecule drugs targeting oncogenic fusion kinasesCancer Res201777133551356328428274
   PubMed Web of Science ®Google Scholar
• SomwarRSmithRHayashiTMDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET -rearranged lung cancersJ Clin Oncol20163415_suppl9068
   Web of Science ®Google Scholar
• Nelson-TaylorSKLeATYooMResistance to RET-Inhibition in RET-Rearranged NSCLC is mediated by reactivation of Ras/MAPK signalingMol Cancer Ther20171681623163328500237
   PubMed Web of Science ®Google Scholar
• DrilonAELiuSDoebeleRLBA19A phase 1B study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with Ret fusion-positive NSCLCAnn Oncol201728suppl_5
   Google Scholar
• ClinicalTrials.gov Identifier: NCT03037385 Available from: https://clini-caltrials.gov/ct2/show/NCT03037385Accessed September 26, 2018
   Google Scholar
• ClinicalTrials.gov Identifier: NCT03157128 Available from: https://clini-caltrials.gov/ct2/show/NCT03157128Accessed September 26, 2018
   Google Scholar
• BesseBSubbiahVDrilonA105 Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (PTS) treated with LOXO-292Ann Oncol201829suppl_8ESMO2018
   Google Scholar
• DrilonALinJJFilleronTFrequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancersJ Thorac Oncol201813101595160130017832
   PubMed Web of Science ®Google Scholar
• SubbiahVBerryJRoxasMSystemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastasesLung Cancer201589767925576294
   PubMed Web of Science ®Google Scholar
• DrilonAESubbiahVOxnardGRA phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET -altered cancersJCO20183615_suppl102
   Web of Science ®Google Scholar
• SubbiahVTaylorMLinJHighly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumorsAACR Meet Abstr Online2018Abstract CT043
   Google Scholar
• KlempnerSJBazhenovaLABraitehFSEmergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKILung Cancer201589335735926187428
   PubMed Web of Science ®Google Scholar
• SchrockABZhuVWHsiehWSReceptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitorsJ Thorac Oncol20181391312132329883838
   PubMed Web of Science ®Google Scholar
• PiotrowskaZIsozakiHLennerzJKLandscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusionCancer Discov20188121529153930257958
   PubMed Web of Science ®Google Scholar